In this proof-of-principle study, we presented experimental evidence that targeting any component in the HMGB1-TLR4-IL-23-IL-17A axis is sufficient to alleviate lung injuries following PQ challenge, justifying its potential as the therapeutic target for correcting PQ-induced ALI. This evidence concerns the gene IL17A and acute respiratory distress syndrome.